atai Life Sciences' PsyProtix to Treat Mental Health Conditions

atai Life Sciences has launched PsyProtix, a precision psychiatry treatment platform for Treatment-Resistant Depression (TRD) through personalized therapies for better treatment.

Fremont, CA:Mental health disorders have a wide range of signs and symptoms that vary from person to person. Recognizing symptoms early and seeking expert help is the greatest approach to avoid mental health problems from worsening. atai Life Sciences, a clinical-stage biopharmaceutical company promising to change the treatment of mental health issues, has launched PsyProtix, a new platform firm developed with Chymia LLC, a Duke University biotechnology spinout.  PsyProtix is a precision psychiatry firm focused on creating treatments for treatment-resistant depression (TRD) and other mental health conditions.

PsyProtix uses a precision psychiatry approach, which is a new area that tries to treat illnesses by taking into account each patient's genetic, metabolic, environmental, and lifestyle variability. Psychiatric patients are traditionally diagnosed and treated using guidelines and protocols created for the majority, which can lead to trial and error as doctors try to satisfy each patient's unique needs.

Instead of depending on trial and error, precision psychiatry allows doctors to prescribe therapies that are precisely tailored to the individual. PsyProtix will concentrate on the metabolomic pathways behind depression symptoms in specific patients in order to develop more personalized treatments.

“Our view is that each patient is unique, meaning that any given patient will likely have specific individual needs,” said Srinivas Rao, Chief Scientific Officer and co-founder of atai Life Sciences. “This emerging technology adapts to the variability of conditions, such as depression, with the aim of allowing patients with psychiatric disorders to potentially be diagnosed and treated more accurately and efficiently according to their specific needs. It’s an honor to be collaborating with Professor Rima Kaddurah-Daouk and her team at Duke, given their great work in advancing the research of metabolomics and their study of neuropsychiatric disorders.”